A Phase 3 interventional study of Lazertinib and Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) in Advanced or Metastatic Non-small Cell Lung Cancer, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 187 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 14 under way, 3 of them phase 3. amivantamab · Carcinoma, Non-Small-Cell Lung.
Among the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 5th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:
Fondazione Ricerca Traslazionale · Sites in Italy
Ages 18–99
SWOG Cancer Research Network · Sites in United States
Ages 18+
University Hospital, Essen · Sites in Belgium, Germany, Netherlands
Ages 18+
Yonsei University
Ages 19+
By country, each count listing its studies:
amivantamab: first FDA approval 2021 (RYBREVANT), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 3
First in 2016; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 418 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 15 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 15 have an industry lead sponsor. The 8 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson: 7 open now, 18 under way, 4 of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, this one is the 7th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2022, is one of 4 in phase 3, reaches primary completion later than 3 of the 17 other live ones, and was the 23rd registered.
Johnson & Johnson’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2012.
7 of the studies testing amivantamab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02609776Janssen Research & Development, LLCStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer | 2026-12-31 |
| NCT04077463Janssen Research & Development, LLCA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer | 2027-02-12 |
| NCT05488314Janssen Research & Development, LLCA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer | 2027-04-28 |
| NCT06120140Janssen Research & Development, LLCEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | 2027-05-31 |
| NCT06784791University Hospital, EssenPreoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Johnson & Johnson’s 36 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lazertinib 240 milligrams (mg) will be administered orally once daily. Participants will receive amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 mg/ 2240 mg depending on the body weight by manual injection. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the long-term extension (LTE) Phase.
Drug: Lazertinib · Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the LTE Phase.
Drug: Lazertinib · Drug: Amivantamab Intravenous
Lazertinib tablets will be administered orally.
Also known as: JNJ-73841937, YH25448
Drug page: Amivantamab
Amivantamab injection will be administered subcutaneously by manual injection.
Also known as: JNJ-61186372
Amivantamab will be administered by IV infusion.
Also known as: JNJ-61186372
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State
Ctrough was the observed serum concentration of Amivantamab at steady state immediately prior to the next drug administration.
Time frame: Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab
Ctrough was the observed serum concentration of Amivantamab immediately prior to the next drug administration.
Time frame: Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)
Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2
AUC (Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15 were reported.
Time frame: Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1
Objective Response Rate (ORR)
Time frame: Up to 3 years 4 months
Progression-Free Survival (PFS)
Time frame: Up to 3 years 4 months
Duration of Response (DOR)
Time frame: Up to 3 years 4 months
Time to Response (TTR)
Time frame: Up to 3 years 4 months
Number of Participants With Adverse Events (AEs)
Time frame: Up to 3 years 4 months
Number of Participants With AEs by Severity
Time frame: Up to 3 years 4 months
Number of Participants With Clinical Laboratory Abnormalities
Time frame: Up to 3 years 4 months
Number of Participants With Clinical Laboratory Abnormalities by Severity
Time frame: Up to 3 years 4 months
Number of Participants With Infusion Related Reactions (IRRs)
Time frame: Up to 3 years 4 months
Number of Participants With IRRs by Severity
Time frame: Up to 3 years 4 months
For All Regions Other Than the EU and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1
Time frame: Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1
Time frame: Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)
Model-Predicted Area Under the Concentration Time Curve of Amivantamab at Steady State From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 4
Time frame: Cycle 4: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hrs post-dose on Day 1; Arm B: preinfusion, EOI+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1
Percentage of Participants With Presence of Anti-amivantamab Antibodies and Anti-rHuPH20 Antibodies
Time frame: Up to 3 years 4 months
Percentage of Participants With Cancer Therapy Satisfaction as Assessed by Therapy Administration Satisfaction Questionnaire (TASQ)
Time frame: Up to 3 years 4 months
Change From Baseline in Therapy Administration Satisfaction Questionnaire (TASQ) as Assessed Over Time
Time frame: From baseline (Day 1, Cycle 1) to 3 years 4 months (each cycle of 28 days)
Participant Chair Time
Time frame: Up to 3 years 4 months
Participant Chair Time in Treatment Room
Time frame: Up to 3 years 4 months
Duration of Treatment Administration
Time frame: Up to 3 years 4 months
Active Health Care Professional (HCP) Time For Drug Preparation, Treatment Administration and Post-treatment Monitoring
Time frame: Up to 3 years 4 months
| Milestone | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion |
|---|---|---|
| Started | 206 | 212 |
| Treated (safety analysis) | 206 | 210 |
| Completed | 43 | 62 |
| Not completed | 163 | 150 |
| Withdrew: Withdrawal by subject | 7 | 8 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other-ongoing | 156 | 141 |
Ctrough was the observed serum concentration of Amivantamab at steady state immediately prior to the next drug administration.
| micrograms per milliliters (mcg/mL) | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion |
|---|---|---|
| For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State | 206 ± 39.1 | 144 ± 41.5 |
Ctrough was the observed serum concentration of Amivantamab immediately prior to the next drug administration.
| mcg/mL | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion |
|---|---|---|
| For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab | 335 ± 32.7 | 293 ± 31.7 |
AUC (Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15 were reported.
| micrograms*hour per milliliters | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion |
|---|---|---|
| Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2 | 135861 ± 30.7 | 131704 ± 24.0 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over All cause mortality: From baseline (Day 1) up to 17 months; SAEs and other AEs: From baseline (Day 1) up to 8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Lazertinib With Amivantamab SC-CF | 43/206 (20.9%) | 59/206 (28.6%) | 201/206 (97.6%) |
| Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion | 61/210 (29%) | 64/210 (30.5%) | 207/210 (98.6%) |
| Event | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion |
|---|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 9/206 | 6/210 |
| PneumoniaInfections and infestations | 3/206 | 7/210 |
| Covid-19Infections and infestations | 4/206 | 4/210 |
| Alanine Aminotransferase IncreasedInvestigations | 4/206 | 3/210 |
| Deep Vein ThrombosisVascular disorders | 2/206 | 4/210 |
| FatigueGeneral disorders | 3/206 | 1/210 |
| Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders | 3/206 | 1/210 |
| NauseaGastrointestinal disorders | 0/206 | 3/210 |
| Cerebral InfarctionNervous system disorders | 0/206 | 3/210 |
| VomitingGastrointestinal disorders | 2/206 | 0/210 |
| Event | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion |
|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 27/206 | 137/210 |
| ParonychiaInfections and infestations | 111/206 | 108/210 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 96/206 | 76/210 |
| RashSkin and subcutaneous tissue disorders | 95/206 | 91/210 |
| StomatitisGastrointestinal disorders | 57/206 | 69/210 |
| Dermatitis AcneiformSkin and subcutaneous tissue disorders | 64/206 | 69/210 |
| NauseaGastrointestinal disorders | 60/206 | 52/210 |
| Oedema PeripheralGeneral disorders | 52/206 | 58/210 |
| Alanine Aminotransferase IncreasedInvestigations | 46/206 | 54/210 |
| Decreased AppetiteMetabolism and nutrition disorders | 45/206 | 52/210 |
| Age, Continuous(years) | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion | Total |
|---|---|---|---|
| Mean | 60.8 ± 9.76 | 61.4 ± 10.71 | 61.1 ± 10.25 |
| Age, Customized(Participants) | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion | Total |
|---|---|---|---|
| <50 years | 28 | 29 | 57 |
| 50-64 years | 105 | 91 | 196 |
| 65-74 years | 55 | 70 | 125 |
| >=75 years | 18 | 22 | 40 |
| Sex: Female, Male(Participants) | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion | Total |
|---|---|---|---|
| Female | 138 | 141 | 279 |
| Male | 68 | 71 | 139 |
| Race (NIH/OMB)(Participants) | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 126 | 129 | 255 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 78 | 77 | 155 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Region of Enrollment(Participants) | Arm A: Lazertinib With Amivantamab SC-CF | Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion | Total |
|---|---|---|---|
| Argentina | 5 | 6 | 11 |
| Australia | 12 | 5 | 17 |
| Brazil | 6 | 11 | 17 |
| Canada | 7 | 11 | 18 |
| China | 46 | 47 | 93 |
| France | 3 | 4 | 7 |
| Germany | 2 | 3 | 5 |
| Israel | 9 | 4 | 13 |
| Italy | 13 | 14 | 27 |
| Japan | 26 | 30 | 56 |
| Malaysia | 8 | 9 | 17 |
| Poland | 3 | 0 | 3 |
| Portugal | 3 | 2 | 5 |
| Korea, South | 21 | 20 | 41 |
| Spain | 14 | 15 | 29 |
| Taiwan | 6 | 6 | 12 |
| Thailand | 5 | 2 | 7 |
| Turkey | 5 | 2 | 7 |
| United Kingdom | 0 | 2 | 2 |
| United States | 12 | 19 | 31 |
Showing the first 100 of 187 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Aug 2022 to primary completion in Jan 2024, 16 months.
Results were first posted in Feb 2026, 2 years after primary completion. A results delay was requested in Dec 2024.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 16 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amivantamab
Carcinoma, Non-Small-Cell Lung →
Janssen Research & Development, LLC →